Symbols / VRPX
VRPX Chart
About
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.67K |
| Enterprise Value | -1.50M | Income | -12.07M | Sales | — |
| Book/sh | -1.53 | Cash/sh | 1.42 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.01 | PEG | — |
| P/S | — | P/B | -0.01 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.61 |
| Current Ratio | 0.63 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -71.00 | EPS next Y | -0.90 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-03 16:00 | ROA | -135.01% |
| ROE | -23.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.24M |
| Shs Float | 1.05M | Short Float | 1.81% | Short Ratio | 0.04 |
| Short Interest | — | 52W High | 7.25 | 52W Low | 0.00 |
| Beta | 1.97 | Avg Volume | 1.91K | Volume | 51.00 |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.01 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-177.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-09 | down | Maxim Group | Buy → Hold | — |
| 2024-07-19 | up | Maxim Group | Hold → Buy | $3 |
| 2024-05-22 | down | Maxim Group | Buy → Hold | — |
- Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com hu, 03 Apr 2025 07
- Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com hu, 03 Apr 2025 07
- VRPX - Virpax Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan Wed, 17 Feb 2021 00
- Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks Mon, 07 Oct 2024 07
- Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today? - InvestorPlace Wed, 10 Jul 2024 07
- Virpax: A Promising Stock In A Sickly Biotech Market - Forbes Sun, 14 Jan 2024 08
- Is Virpax Pharmaceuticals (VRPX) Stock a Buy? - Benzinga Mon, 23 Aug 2021 07
- Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com Wed, 19 Mar 2025 07
- Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Stock Titan hu, 08 Aug 2024 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace ue, 18 Jun 2024 07
- Why Is HilleVax (HLVX) Stock Down 87% Today? - InvestorPlace Mon, 08 Jul 2024 07
- Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com Fri, 04 Oct 2024 07
- GRFS Stock Alert: Grifols Pops 20% on Takeover Interest - InvestorPlace Mon, 08 Jul 2024 07
- Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World Wed, 25 Feb 2026 06
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.96M | -18.19M | -21.85M | -11.96M |
| TotalUnusualItems | 1.25M | |||
| TotalUnusualItemsExcludingGoodwill | 1.25M | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.07M | -15.19M | -21.65M | -12.06M |
| EBITDA | -11.96M | -16.94M | -21.85M | -11.96M |
| EBIT | -11.96M | -16.94M | -21.85M | -11.96M |
| NetInterestIncome | -103.75K | 0.00 | -92.82K | |
| InterestExpense | 103.75K | 0.00 | 92.82K | |
| NormalizedIncome | -12.07M | -16.44M | -21.65M | -12.06M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.07M | -15.19M | -21.65M | -12.06M |
| TotalExpenses | 12.08M | 16.94M | 21.85M | 12.03M |
| TotalOperatingIncomeAsReported | -12.08M | -15.69M | -21.85M | -12.03M |
| DilutedAverageShares | 46.85K | 46.85K | 26.71K | |
| BasicAverageShares | 46.85K | 46.85K | 26.71K | |
| DilutedEPS | -324.25 | -462.50 | -452.50 | |
| BasicEPS | -324.25 | -462.50 | -452.50 | |
| DilutedNIAvailtoComStockholders | -12.07M | -15.19M | -21.65M | -12.06M |
| NetIncomeCommonStockholders | -12.07M | -15.19M | -21.65M | -12.06M |
| NetIncome | -12.07M | -15.19M | -21.65M | -12.06M |
| NetIncomeIncludingNoncontrollingInterests | -12.07M | -15.19M | -21.65M | -12.06M |
| NetIncomeContinuousOperations | -12.07M | -15.19M | -21.65M | -12.06M |
| TaxProvision | 0.00 | 0.00 | 0.00 | |
| PretaxIncome | -12.07M | -15.19M | -21.65M | -12.06M |
| OtherIncomeExpense | 116.46K | 1.75M | 194.41K | 62.26K |
| OtherNonOperatingIncomeExpenses | 116.46K | 500.28K | 194.41K | 62.26K |
| SpecialIncomeCharges | 1.25M | |||
| OtherSpecialCharges | -1.25M | |||
| NetNonOperatingInterestIncomeExpense | -103.75K | 0.00 | -92.82K | |
| InterestExpenseNonOperating | 103.75K | 0.00 | 92.82K | |
| OperatingIncome | -12.08M | -16.94M | -21.85M | -12.03M |
| OperatingExpense | 12.08M | 16.94M | 21.85M | 12.03M |
| ResearchAndDevelopment | 5.82M | 5.12M | 10.76M | 4.84M |
| SellingGeneralAndAdministration | 6.26M | 11.82M | 11.08M | 7.19M |
| GeneralAndAdministrativeExpense | 6.26M | 11.82M | 11.08M | 7.19M |
| OtherGandA | 6.26M | 11.49M | 11.08M | 7.19M |
| SalariesAndWages | 335.36K | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 595.50K | 46.85K | 46.86K | 46.86K |
| ShareIssued | 595.50K | 46.85K | 46.86K | 46.86K |
| TangibleBookValue | -913.76K | 1.93M | 16.58M | 37.48M |
| InvestedCapital | -913.76K | 1.93M | 16.58M | 37.48M |
| WorkingCapital | -913.76K | 1.93M | 16.58M | 37.48M |
| NetTangibleAssets | -913.76K | 1.93M | 16.58M | 37.48M |
| CommonStockEquity | -913.76K | 1.93M | 16.58M | 37.48M |
| TotalCapitalization | -913.76K | 1.93M | 16.58M | 37.48M |
| TotalEquityGrossMinorityInterest | -913.76K | 1.93M | 16.58M | 37.48M |
| StockholdersEquity | -913.76K | 1.93M | 16.58M | 37.48M |
| RetainedEarnings | -71.61M | -59.54M | -44.35M | -22.70M |
| AdditionalPaidInCapital | 70.70M | 61.48M | 60.93M | 60.19M |
| CapitalStock | 149.00 | 12.00 | 12.00 | 117.00 |
| CommonStock | 149.00 | 12.00 | 12.00 | 117.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.47M | 7.69M | 3.09M | 2.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.47M | 7.69M | 3.09M | 2.09M |
| OtherCurrentLiabilities | 6.00M | 2.00M | ||
| CurrentDeferredLiabilities | 0.00 | |||
| PayablesAndAccruedExpenses | 2.47M | 1.69M | 1.09M | 2.09M |
| CurrentAccruedExpenses | 2.43M | 1.68M | 1.06M | 2.07M |
| InterestPayable | 0.00 | |||
| Payables | 41.06K | 18.46K | 37.64K | 19.84K |
| OtherPayable | 41.06K | 18.46K | 37.64K | 19.84K |
| TotalTaxPayable | 8.00K | |||
| TotalAssets | 1.56M | 9.63M | 19.67M | 39.57M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredAssets | 0.00 | |||
| CurrentAssets | 1.56M | 9.63M | 19.67M | 39.57M |
| OtherCurrentAssets | 34.83K | 67.22K | 25.34K | 2.47M |
| CurrentDeferredAssets | 3.08K | 0.00 | ||
| PrepaidAssets | 4.64K | 419.61K | 653.02K | 255.85K |
| CashCashEquivalentsAndShortTermInvestments | 1.51M | 9.14M | 19.00M | 36.84M |
| CashAndCashEquivalents | 1.51M | 9.14M | 19.00M | 36.84M |
| CashFinancial | 1.51M | 9.14M | 19.00M | 36.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.71M | -9.85M | -17.85M | -14.54M |
| RepaymentOfDebt | 0.00 | -1.60M | ||
| IssuanceOfDebt | 0.00 | 100.00K | ||
| IssuanceOfCapitalStock | 6.32M | 0.00 | 0.00 | 58.02M |
| InterestPaidSupplementalData | 0.00 | 362.82K | ||
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 1.51M | 9.14M | 19.00M | 36.84M |
| BeginningCashPosition | 9.14M | 19.00M | 36.84M | 54.80K |
| ChangesInCash | -7.63M | -9.85M | -17.85M | 36.79M |
| FinancingCashFlow | 9.08M | 0.00 | 0.00 | 51.33M |
| CashFlowFromContinuingFinancingActivities | 9.08M | 0.00 | 0.00 | 51.33M |
| NetOtherFinancingCharges | -5.19M | |||
| ProceedsFromStockOptionExercised | 2.77M | 0.00 | ||
| NetCommonStockIssuance | 6.32M | 0.00 | 0.00 | 58.02M |
| CommonStockIssuance | 6.32M | 0.00 | 0.00 | 58.02M |
| NetIssuancePaymentsOfDebt | 0.00 | -1.50M | ||
| NetShortTermDebtIssuance | 0.00 | -1.50M | ||
| ShortTermDebtPayments | 0.00 | -1.60M | ||
| ShortTermDebtIssuance | 0.00 | 100.00K | ||
| NetLongTermDebtIssuance | -1.50M | |||
| LongTermDebtPayments | -1.60M | |||
| LongTermDebtIssuance | 100.00K | |||
| OperatingCashFlow | -16.71M | -9.85M | -17.85M | -14.54M |
| CashFlowFromContinuingOperatingActivities | -16.71M | -9.85M | -17.85M | -14.54M |
| ChangeInWorkingCapital | -4.78M | 4.79M | 3.06M | -3.40M |
| ChangeInOtherCurrentLiabilities | -6.00M | 4.00M | 2.00M | 0.00 |
| ChangeInPayablesAndAccruedExpense | 775.35K | 599.43K | -993.10K | -686.78K |
| ChangeInPayable | -686.78K | |||
| ChangeInAccountPayable | -686.78K | |||
| ChangeInPrepaidAssets | 444.28K | 191.53K | 2.05M | -2.71M |
| StockBasedCompensation | 134.70K | 544.77K | 745.03K | 974.23K |
| OperatingGainsLosses | -61.82K | |||
| NetIncomeFromContinuingOperations | -12.07M | -15.19M | -21.65M | -12.06M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for VRPX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|